Drying droplets have fascinated scientists for decades. From water to coffee to paint, these everyday fluids leave behind intricate patterns as they evaporate. But blood is far more complex—a colloidal suspension packed with red blood cells, plasma proteins, salts, and countless biomolecules.

As blood dries, it leaves behind a complex microstructural pattern—cracks, rings, and folds—each shaped by the interplay of its cellular components, proteins, and evaporation dynamics. These features form a kind of physical fingerprint, quietly recording the complex interplay of physics that unfolded during the desiccation of the droplet.

In our recent experiments, we explored how blood droplets dry by varying both their size—from tiny 1-microliter drops to larger 10-microliter ones—and the angle of the surface, from completely horizontal to a steep 70° incline. Using an optical microscope, a high-speed camera, and a surface profiler, we tracked how the droplets dried, shrank and cracked.

“Our data shows that Oropouche virus is massively under-diagnosed in Latin America,” says Drexler, who also conducts research at the German Center for Infection Research (DZIF). “In some areas, at least one person in ten has experienced a prior infection with the pathogen.”

More widespread than thought – but still insufficiently investigated

Oropouche virus causes nonspecific symptoms such as fever, chills, headache, pain in the limbs, and, in some cases, nausea and skin rashes. For a long time, the disease was considered to be predominantly mild, and reports of more severe bouts, including meningitis, were rare.

Aiming to reduce recurrent stroke in patients with embolic stroke of unknown source (ESUS), recent trials have compared direct oral anticoagulants (DOACs) to aspirin, but results have been neutral. For example, the ARCADIA trial compared apixaban versus aspirin in patients with ESUS and evidence of atrial cardiopathy, finding no difference. Now, researchers report results of an MRI substudy of ARCADIA, in which patients underwent a baseline and end-of-study MRI. This analysis compares the rate of MRI-detected covert (silent), nonlacunar stroke in the two treatment groups.

Of the 1,015 patients in the parent trial, 310 patients enrolled in the MRI substudy, of whom 174 patients had image quality sufficient for analysis. In these 174 patients (mean age, 66 years; 48% women), the aspirin group had higher rates of diabetes (30% vs. 20%) and previous stroke or transient ischemic attack (26% vs. 15%). During a median follow-up of 811 days, the rate of covert nonlacunar infarcts was significantly lower in the apixaban group than the aspirin group (5% vs. 18%). However, rates of symptomatic nonlacunar stroke did not differ significantly between the two groups (4% apixaban, 8% aspirin; P =0.30).

This study is useful for hypothesis generation, but it is not conclusive. The patients in the MRI substudy were imbalanced in key baseline characteristics, and the small overall number of outcome events makes the results tenuous. Right now, DOACs are not first-line treatment for patients with ESUS-type strokes.